Streetbeat News

TEM

Tempus AI Inc.

Industry

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Open

35.15

Mkt cap

5.4B

Volume

2.4M

High

35.93

P/E Ratio

-6.81

52-wk high

79.49

Low

34.35

Div yield

N/A

52-wk low

22.89

Tempus AI's preliminary Q4 results show mixed performance with revenue slightly below expectations. However, the company anticipates positive adjusted EBITDA for 2025, driven by the Ambry Genetics acquisition. Tempus AI's strong fundamentals and competitive position support long-term growth in diagnostics and AI applications in healthcare.

Portfolio Pulse from

January 15, 2025 | 10:00 am

Tempus (TEM) stock declines after missing preliminary Q4 sales estimates. Despite this, the company reports strong growth for 2024 and projects a 75% revenue increase in 2025, driven by innovative diagnostics.

Portfolio Pulse from

January 14, 2025 | 2:30 pm

Tempus AI's stock fell despite announcing a collaboration with Genialis to develop RNA-based algorithms for cancer treatment.

Portfolio Pulse from

January 09, 2025 | 3:15 pm

Tempus AI's stock has surged by 23% over the past six months, driven by its innovative product lines and strategic plans, which are positioning the company for long-term success.

Portfolio Pulse from

January 07, 2025 | 5:45 pm

Tempus AI's stock has dropped 28.9% over the past three months. The company is working on enhancing its offerings and expanding its product and service range to improve patient care. However, macroeconomic challenges are expected to negatively impact its performance.

Portfolio Pulse from

December 24, 2024 | 5:45 pm

Tempus AI, listed on NASDAQ as TEM, experienced significant volatility after its IPO. Initially up by 93%, the stock is now 8% below its opening price of $37 as of December 18.

Portfolio Pulse from

December 20, 2024 | 2:00 pm

Tempus AI, despite recent stock volatility due to lock-up expiration and insider selling, shows strong long-term potential in healthcare technology. Its 'Intelligent Diagnostics' uses generative AI for personalized treatments, positioning it as a leader in precision medicine. The company is experiencing robust revenue growth but is still unprofitable, with recent acquisitions and investments aimed at strengthening its market position.

Portfolio Pulse from

December 18, 2024 | 4:00 am

Tempus AI is enhancing its growth and competitive edge in AI health tech through strategic acquisitions and partnerships, including Ambry Genetics and a joint venture with SoftBank. The company's Data & Services division shows promising revenue growth and gross margins, positioning it for future profitability.

Portfolio Pulse from

December 08, 2024 | 12:15 pm

Tempus AI has acquired Ambry Genetics, which will expand its testing portfolio and redefine precision medicine. This acquisition is expected to enhance Tempus AI's capabilities in the field of genetic testing and precision medicine.

Portfolio Pulse from

November 25, 2024 | 7:45 pm

Tempus AI, Inc., a company leveraging AI for precision medicine, has shown strong growth since its June 2024 listing. It presents a buying opportunity due to its vast data library, advanced AI algorithms, and partnerships with Merck and BioNTech. Despite concerns over profitability and cash burn, its revenue growth and strategic acquisitions make it a compelling long-term investment.

Portfolio Pulse from

November 12, 2024 | 10:15 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.